dc.contributor.author | Prodromou, C | |
dc.date.accessioned | 2018-08-29T08:36:07Z | |
dc.date.issued | 2009-11 | |
dc.identifier | 15 | |
dc.identifier.citation | CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 pp. 1352 - 1368 | |
dc.identifier.issn | 1568-0266 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2388 | |
dc.identifier.doi | 10.2174/156802609789895656 | |
dc.description.abstract | Hsp90 is involved in the maturation and activation of client proteins. Often these are key proteins involved in signal transduction and regulatory pathways that in a mutated and/or deregulated form sustain an oncogenic cellular state. Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity. The requirement for the Hsp90 chaperone machine to drive the malignancy makes Hsp90 a prime anticancer target, an ‘axle in a wheel’ that when disrupted has been shown to be effective in killing cancerous cells. This review aims to identify potential drug targets, based on the current structural knowledge of the Hsp90-chaperone machine, that could be targeted with the aim of disrupting its functioning and promoting an anti-cancer activity. | |
dc.format.extent | 1352 - 1368 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | BENTHAM SCIENCE PUBL LTD | |
dc.title | Strategies for Stalling Malignancy: Targeting Cancer’s Addiction to Hsp90 | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.2174/156802609789895656 | |
rioxxterms.licenseref.startdate | 2009-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | CURRENT TOPICS IN MEDICINAL CHEMISTRY | |
pubs.notes | affiliation: Prodromou, C (Reprint Author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England. Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England. keywords: Heat shock protein; Hsp90; co-chaperones; cancer; drug design keywords-plus: HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI HSP90; N-TERMINAL DOMAIN; PHASE-II TRIAL; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ATPASE CYCLE; STEROID-RECEPTOR; ANTICANCER AGENT; STRUCTURAL BASIS research-areas: Pharmacology & Pharmacy web-of-science-categories: Chemistry, Medicinal author-email: [email protected] orcid-numbers: Prodromou, Chrisostomos/0000-0003-4320-1147 number-of-cited-references: 138 times-cited: 19 usage-count-last-180-days: 1 usage-count-since-2013: 3 journal-iso: Curr. Top. Med. Chem. doc-delivery-number: 532WZ unique-id: ISI:000272782400003 da: 2018-08-24 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR | |
pubs.volume | 9 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Prodromou, Chrisostomos | en |